Chandler Robinson - May 28, 2024 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Executive Officer, Director
Signature
/s/ Kim R Tsuchimoto, Attorney-in-fact
Stock symbol
MNPR
Transactions as of
May 28, 2024
Transactions value $
$84
Form type
4
Date filed
5/30/2024, 06:10 PM
Previous filing
Apr 2, 2024
Next filing
Jul 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNPR Common Stock Exercise of in-the-money or at-the-money derivative security $84.00 +84K +50.56% $0.00* 250K May 28, 2024 Direct F1
holding MNPR Common Stock 4.11M May 28, 2024 See Footnote F2
holding MNPR Common Stock 167K May 28, 2024 See Footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Stock Options Exercise of in-the-money or at-the-money derivative security $0 -84K -100% $0.00* 0 May 28, 2024 Common Stock 84K $0.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.
F2 This is based upon the 4,111,272.88 shares of Monopar Common Stock that Tactic Pharma LLC indirectly controls through TacticGem LLC. As a manager of Tactic Pharma LLC, Dr. Robinson may be deemed to share voting and dispositive power over these 4,111,272.88 shares. Dr. Robinson disclaims beneficial ownership of the 4,111,272.88 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein.
F3 This is based upon the 166,667 shares of Monopar Common Stock that Tactic Pharma LLC directly owns. As a manager of Tactic Pharma LLC, Dr. Robinson may be deemed to share voting and dispositive power over these 166,667 shares. Dr. Robinson disclaims beneficial ownership of the 166,667 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein
F4 Reflects options to purchase up to 84,000 shares of common stock granted to Dr. Robinson on April 4, 2016 for his services as a director and officer of Monopar Therapeutics. The options vested 50% upon grant date, 25% upon the 6-month anniversary of grant date, and 25% upon the 1-year anniversary of grant date.